Key facts
- This page summarizes John A. Orwin's Form 4 filing for ANAPTYSBIO, INC (ANAB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jun 2024, 20:15.
John A. Orwin - 15 Jun 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)
- Reporting relationship
- Director
- Issuer ticker
- ANAB
- Reported as of
- 15 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jun 2024, 20:15:41 UTC
- Prior SEC filing
- 06 Jun 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Loumeau, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John A. Orwin filed Form 4 for ANAPTYSBIO, INC (ANAB) on 18 Jun 2024.
Change
- Previous filing in this sequence was filed on 06 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANAB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +2,035
- Change %
- Price
- $0.000000
- Shares after
- 2,035
- Date
- 15 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANAB
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -2,035
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,035
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F2
The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.